{{Notability|1=Companies|date=May 2025}} {{Infobox company | traded_as = {{NASDAQ|AXGN}}<br>Russell 2000 Component }}
'''Axogen''' is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida.<ref>{{Cite press release|last=Inc|first=Axogen|date=2020-05-06|title=Axogen, Inc. Reports First Quarter 2020 Financial Results|url=http://www.globenewswire.com/news-release/2020/05/06/2028796/0/en/Axogen-Inc-Reports-First-Quarter-2020-Financial-Results.html|access-date=2020-06-03|website=GlobeNewswire News Room}}</ref> Axogen products are designed to remedy peripheral nerve damage.<ref>{{Cite magazine |date=February 2011 |title=Axogen, a peripheral |url=https://link.gale.com/apps/doc/A255842035/ITOF?u=wikipedia&sid=bookmark-ITOF&xid=be5d0e32 |magazine=Medical Marketing & Media |publisher=Haymarket Media |publication-place=London |volume=46 |issue=2 |page=17 |access-date=22 June 2023 |via=Gale General OneFile (Wikipedia Library)}}</ref><ref>{{Cite news |last=Beck |first=Melinda |date=26 December 2012 |title=Graft Helps Nerves Regrow |website=The Wall Street Journal |url=https://webreprints.djreprints.com/3083940389182.html |url-status=dead |access-date= |archive-url=https://web.archive.org/web/20130304113321/https://webreprints.djreprints.com/3083940389182.html |archive-date=4 March 2013}}</ref><ref>{{Cite web |last=Joseph |first=Drew |date=19 February 2013 |title=Nerve repair using grafts from cadavers |url=https://www.sfgate.com/health/article/Nerve-repair-using-grafts-from-cadavers-4291692.php |access-date=23 June 2023 |website=SFGATE}}</ref> In 2013 the company raised $18 million in its initial public offering (IPO).<ref name="trend">[Alachua] Business Briefs November 2013 Florida Trend Magazine</ref> Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes.<ref>{{Cite web|url=https://www.bloomberg.com/profile/company/AXGN:US|access-date=2020-06-03|website=www.bloomberg.com|title=Axogen Inc - Company Profile and News }}</ref> The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration (FDA) for clinical use.{{cn|date=August 2020}}
==See also==
==References== {{reflist}}
{{Florida-stub}}
Category:Biotechnology companies of the United States Category:Companies based in Florida